A renaissance in targeting the PI3K/AKT/mTOR pathway www.nature.com/articles/s41... rdcu.be/faYxr This new Perspective discusses how advances in understanding of PI3K signalling in disease and novel pharmacological strategies are revitalizing interest in targeting the pathway

For readers interested in novel drugs for chronic obstructive pulmonary disease, such as AstraZeneca's IL-33 inhibitor tozorakimab, here's a recent review www.nature.com/articles/s41... rdcu.be/faMN3

AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population. endpoints.news/astrazenecas...

First-in-class blood–brain barrier shuttle wins FDA nod for Hunter syndrome www.nature.com/articles/d41... Denali Therapeutics’ tividenofusp alfa - an enzyme fused to a blood–brain barrier-penetrating Fc domain - showcases an emerging approach to better get complex drugs into the brain

The therapeutic potential of orphan adhesion G-protein-coupled receptors nature.com/articles/s41... rdcu.be/e52UX This Review discusses opportunities to target adhesion GPCRs in cancer, psychiatric disorders and autoimmune diseases, based on advances in structural biology

Wearable technologies in clinical trials for drug development: trends and emerging opportunities rdcu.be/e9L7x www.nature.com/articles/s41... This new Review summarizes the characteristics of classes of wearable technologies, and analyses their use in drug trials and the regulatory landscape

Can a first disease-modifying osteoarthritis drug make it past the FDA? www.nature.com/articles/d41... Biosplice says its dual CLK and DYRK kinase inhibitor reduces pain and slows joint damage. Up and coming localized gene therapies have the same goal

Alex Eccleston, Senior Editor at Nature Reviews Drug Discovery, will be attending the SMR conference ‘Target To Patient 2026’ on 20-21 April www.smr.org.uk/Meetings/202... @socmedres.bsky.social

Single-dose sleeping sickness drug set for approval www.nature.com/articles/d41... The antiparasitic drug acoziborole, developed through a collaboration between DNDi and Sanofi, could play a key role in efforts to eliminate the disease in Africa

Epigenetic editing: from concept to clinic www.nature.com/articles/s41... rdcu.be/e8NlG This Review in the March issue covers approaches to reprogramme gene expression by rewriting epigenetic signatures, and discusses challenges including target specificity and delivery

Induced proximity-based therapeutic modalities www.nature.com/articles/s41... rdcu.be/e8CrR This Review in the March issue covers the range of therapeutic modalties that act by inducing interactions between biomolecules, including molecular glues and bifunctional molecules

Upcoming FDA approval decisions in Q2 2026 www.nature.com/articles/d41... Notable drug candidates with FDA approval decisions anticipated in Q2 include baxdrostat for hypertension, orforglipron for obesity and vepdegestrant for ESR1-mutant metastatic breast cancer

Reshaping Pfizer’s drug discovery priorities www.nature.com/articles/d41... Chris Boshoff, Pfizer’s CSO and President of R&D, discusses the company's renewed focus on oncology, obesity drugs and more in our latest interview

Reshaping Pfizer’s drug discovery priorities nature.com/articles/d41... Chris Boshoff, Pfizer’s CSO and President of R&D, discusses the company's renewed focus on oncology, obesity drugs and more in our latest interview

Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges rdcu.be/e8qhG www.nature.com/articles/s41... This Review in the March issue discusses generating and maintaining organoids, and their applications in disease modelling and drug screening

For readers interested in GLP-1-based therapies such as tirzepatide for treating diabetes, obesity and more, here's a review rdcu.be/e7TFI www.nature.com/articles/s41...

Top companies and drugs by sales in 2025 nature.com/articles/d41... Driven by the success of its GLP-1 drug tirzepatide, Lilly surged to the top of the company rankings by drug sales in 2025, with ~$61 billion in total. Read more in this article by Paul Verdin @evaluatepharma.bsky.social

For readers interested in synthetic lethality in cancer drug discovery, here's a recent comprehensive review rdcu.be/e7B1C nature.com/articles/s41...

Our latest resesarch highlight covers a paper in Nature Chemical Biology presenting a synthetic lethality strategy to target p53-deficient cancers nature.com/articles/d41...

Our March issue is live! Read about induced proximity-based therapeutic modalities, organoids in drug discovery, epigenetic editing, lessons learned from the failures in targeting TIGIT in cancer and more here www.nature.com/nrd/volumes/...

For readers interested in drug repurposing, this review summarizes the approaches, evaluates available in silico resources and presents case studies www.nature.com/articles/s41... rdcu.be/e60em

This research highlight covers a recent study involving a computational drug repurposing screen to identify compounds that could promote remyelination in multiple sclerosis www.nature.com/articles/d41...

Digital endpoints in clinical trials: building the business case for systematic adoption www.nature.com/articles/d41... This new article discusses the operational and financial impact of digital endpoints in clinical development, including cases where they have been successfully used

The JAK–STAT pathway is an important target for drugs for inflammatory and autoimmune disorders. This Review discusses recent advances in JAK and STAT inhibitor development and highlights emerging therapeutic indications nature.com/articles/s41... rdcu.be/eXDui

We are constantly reminded that the most promising ideas still have to be proven in the clinic - and that the first trial is almost never enough. If you've never heard of TIGIT, it's yet another cautionary tale:

Dose-finding and optimization in drug development for rare diseases www.nature.com/articles/d41... This new article discusses approaches to determining the dose of a drug for rare diseases, which is more challenging than typical because so few patients are involved in clinical trials

The therapeutic potential of orphan adhesion G-protein-coupled receptors www.nature.com/articles/s41... rdcu.be/e52UX This new Review discusses opportunities to target aGPCRs in cancer, psychiatric disorders and autoimmune diseases, based on advances in structural biology

For readers interested in CAR-T cell therapies for cancer, here's a review on strategies to manage their toxicity nature.com/articles/s41... rdcu.be/e5OQP

Gilead pays US$7.8 billion for Arcellx’s next-generation CAR T candidate www.nature.com/articles/d41...

Approvals by the China NMPA in 2025 www.nature.com/articles/d41... Last year was the first when approvals of drugs developed in China outnumbered those of imported drugs. Find out more in this analysis

CAR-T cell therapies that deplete pathogenic B cells have recently shown promise in clinical trials for autoimmune diseases such as lupus. This Review discusses the prospects and challenges in the field rdcu.be/e5vPk www.nature.com/articles/s41...

For readers interested in the opportunities and challenges for bespoke gene therapies (N-of-1) that could be eligible for the FDA's new plausible mechanism pathway, here's a roadmap from the International Rare Diseases Research Consortium rdcu.be/e5uKr nature.com/articles/s41...

NEW: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications, w/ @jasonmast.bsky.social www.statnews.com/2026/02/23/f...

Great to see our work to engineer AbLecs as a new immunotherapy modality featured in @natrevdrugdiscov.nature.com! www.nature.com/articles/d41...

The pancreatic cancer drug market www.nature.com/articles/d41... This new article analyses the late-stage pipeline of drugs being developed for pancreatic cancer and the potential impact on the market

This Review considers the blood-brain barrier as a therapeutic target and discusses approaches to its repair and protection in specific diseases such as Alzheimer's disease, as well as during normal ageing www.nature.com/articles/s41... rdcu.be/e4Kr6

Review @natrevdrugdiscov.nature.com Therapeutic targeting of neuroimmune mechanisms in neurodegeneration www.nature.com/articles/s41...

Does TIGIT benefit no one… Or does it benefit a biologically defined subset we failed to identify? 🤔 All-comers trials and conventional biomarkers ignore heterogeneous tumour immune contexts. Is it time for true precision IO? 🔬 #ImmunoOncology #PrecisionMedicine #Biomarkers

Therapeutic targeting of neuroimmune mechanisms in neurodegeneration www.nature.com/articles/s41... rdcu.be/e4y3u This new Review covers neuroimmune interactions in the context of neurogenerative diseases such as Alzheimer disease and progress with drugs targeting microglia

TIGIT’s immuno-oncology teachings www.nature.com/articles/d41... Drug developers spent billions of dollars on clinical trials of TIGIT-blocking cancer immunotherapies, but have little to show for it. What went wrong?

In vivo CAR-T cell therapy platforms, such as the one underlying Lilly's $2.4 billion acquisition of Orna, and their potential for cancer and autoimmune diseases are discussed in this Review in the February issue rdcu.be/e3R3n www.nature.com/articles/s41...

Lilly bets on next-generation cell therapy with $2.4 billion deal for Orna reut.rs/4kvXnUG

Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety rdcu.be/e3GLd www.nature.com/articles/s41... This Perspective in the February issue discusses QST models for major organs and applying them to support safety decisions

For readers interested in vaccines for cancer prevention, here's a Review rdcu.be/e3vcH www.nature.com/articles/s41...

Unlocking the potential of disease prevention through regulatory science nature.com/articles/d41... This new Comment article provides regulatory and drug development recommendations to help unlock the potential of disease prevention

For readers interested in the application of biomarkers, here's a Review on biomarker-guided decision making in drug development for neurodegenerative disorders rdcu.be/e3jHt nature.com/articles/s41...

The Biomarkers Consortium: 20 years of advancing precision medicine nature.com/articles/d41... This article highlights contributions from the FNIH Biomarkers Consortium in advancing biomarkers to enable disease monitoring, earlier interventions and improved outcomes

For readers interested in new drugs for chronic obstructive pulmonary disease, this Review article in the February issue analyses progress in the field and drugs in the pipeline such as PDE3/4 inhibitors rdcu.be/e27dW nature.com/articles/s41...

This article in the February issue analyses M&As and partnerships in the biopharma industry in 2025, with GSK's potential $12.5 billion partnership with Hengrui Pharmaceuticals focused on a PDE3/4 inhibitor for COPD in the top spot for licensing deals nature.com/articles/d41...

Review @natrevdrugdiscov.nature.com @grieshaber.bsky.social @biohacker.bsky.social Roads and detours for CAR T cell therapy in autoimmune diseases www.nature.com/articles/s41...